WASHINGTON— The Endocrine Society is pleased to announce its Rare Endocrine Disease (RED) Fellows Program designed to equip early career physicians with the knowledge and practical skills needed to improve outcomes for people living with rare endocrine diseases.
The program was developed in partnership with the National Organization for Rare Disorders (NORD) and addresses critical gaps in awareness, diagnosis and care of rare endocrine diseases.
The program consists of two core components:
The program accepts up to 50 domestic fellows, and the deadline for program directors and other faculty to nominate a fellow is March 2, 2026.
For more details on the program, including eligibility, learning objectives and the program agenda, visit endocrine.org/education-and-training/rare-endocrine-disease-fellows-program.
This program is supported by educational grants from Alexion Pharmaceuticals, Inc., Neurocrine Biosciences, Inc., BridgeBio Pharma, Inc., Chiesi USA, Inc., Corcept Therapeutics, Inc., and Crinetics Pharmaceuticals, Inc.
# # #
Endocrinologists are at the core of solving the most pressing health problems of our time, including diabetes, obesity, infertility, bone health, and hormone-related cancers. The Endocrine Society is the largest global organization of scientists devoted to hormone research and physicians who care for people with hormone-related conditions.
With more than 18,000 members in 133 countries, the Society serves as the voice of the endocrine field. Through its renowned journals and ENDO, the world's largest endocrine meeting, the Society accelerates hormone research, advances clinical excellence in endocrinology, and advocates for evidence-based policies on behalf of the global endocrine community. To learn more, visit our online newsroom .